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Studies that either 1) model the likelihood of clinical met during the 1987 Regenstrief Conference identified 
outcomes as a function of patient characteristics, or 2) several important areas for further attention. Described are 
examine the factors underlying a specific medical decision discussions on ways to improve standardization, accessibil- 
are discussed. Although the currently available models ity, validation and dissemination of decision models. 
represent important contributions, the working group that (J Am Co11 Cardiol1989;14:52A-4A) 
Current Issues in Cardiovascular Modeling 
Cardiovascular modeling is a very broad topic, and we 
have chosen to focus primarily on modeling that supports 
clinical decision making. Projects such as those in cardio- 
vascular physiology or pharmacokinetics that include mod- 
eling but are not aimed at supporting clinical decision making 
are beyond the scope of this review. We discuss here studies 
that either 1) model the likelihood of clinical outcomes as a 
function of patient characteristics, or 2) critically examine 
the factors underlying a specific medical decision. 
Cardiovascular modeling projects may be classified ac- 
cording to the project’s clinical focus (Table I). Most car- 
diovascular models have concerned manifestations of coro- 
nary artery disease, primarily chronic stable angina pectoris 
and acute myocardial ischemia syndromes (including acute 
myocardial infarction and unstable angina). There have been 
some models of syncope and ventricular arrhythmias, but 
relatively few that examine valvular disease, congenital 
disease, pericardial disease and other less common cardiac 
disorders. Examples of these applications and the associated 
investigators are listed in Table I. 
Another way to classify cardiovascular modeling projects 
is according to the methodology they employ. The major 
categories then become 1) clinical prediction rules for diag- 
nosis, triage or prognosis, and 2) decision models that focus 
on clinical or cost-effectiveness outcomes. The models in 
Table 1 are cross-classified with use of this schema. 
The cardiovascular models cited in Table 1 represent 
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important contributions. Nevertheless, the working group 
identified a number of important areas that deserve further 
attention. The following sections describe ways to improve 
the standardization, accessibility, validation and dissemina- 
tion of models. 
Standardization of Variables in 
Cardiovascular Models 
Several barriers block more widespread use of cardiovas- 
cular models (Table 2). One substantial barrier is the lack of 
standardization in the definition and measurement of key 
variables in models. Lack of standardization may not only 
add “noise” to the system, but in some instances may 
introduce systematic deviations (or bias) in the performance 
of models. Purely clinical variables have the greatest poten- 
tial for different definitions among centers. For example, the 
classification of angina as typical or atypical, stable or 
unstable, progressive or crescendo, class II or class III or 
“medically unresponsive” may differ considerably among 
institutions. Even more “objective” data such as electrocar- 
diographic findings may be interpreted quite differently in 
different institutions, especially in the absence of standard 
coding. Variations in either the definition or measurement of 
such key variables can make transfer of models to another 
institution difficult. 
Greater standardization of nomenclature could facilitate 
the adoption of cardiovascular models outside the institu- 
tions that developed them. Professional associations such as 
the American College of Cardiology or the American Heart 
Association could devise and promulgate standards for no- 
menclature. The role of multicenter trials in standardization 
can also be considerable because standardization of the 
definitions of clinical variables across leading centers of 
cardiovascular investigation is a prerequisite for the conduct 
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Table 1. Projects and Leading Investigators in Clinical Cardiovascular Modeling 
I. Diagnosis 
A. Angina pectoris 
I. George Diamond: CADENZA; Cedars-Sinai Medical Center, Los Angeles. California (I .2) 
2. David Pryor: Duke Cardiovascular Disease Database: Duke University Medical Center. Durham. North Carolina (3) 
3. Robert Detrano: Veterans Administration Medical Center. Long Beach, California and Cleveland Clinic, Cleveland, Ohio (4) 
B. Acute myocardial infarction 
I. Harry Selker, Ralph D’Agostino, Michael Pozen: Tufts-New england Medical Center. Boston. Massachusetts (5) 
2. Lee Goldman: Brigham and Women’s Hospital Boston, Massachusetts (6) 
3. Harold Sox: Stanford University, Palo Alto, California (7) 
II. Prognosis 
A. Chronic coronary artery disease 
I. Duke Cardiovascular Disease Database (8-l I) 
2. Kathryn Davis, Lloyd Fisher: Coronary Artery Surgery Study (CASS) Coordinating Center. Seattle, Washington (12.13) 
3. Katherine Detre: Veterans Administration Cooperative Study and National Heart. Lung. and Blood Institute Percutaneous Transluminal Coronary 
Angioplasty (PTCA) Registry. Pittsburgh, Pennsylvania (14.15) 
B. Acute coronary artery disease 
I. William Knaus: APACHE; George Washington University. Washington. D.C. (16) 
2. Elizabeth Gilpin. Erling Birk Madsden. John Ross. Jr.: University of California. San Diego. California (17.18) 
3. Arthur Moss: Multicenter Postinfarction Research Group. Rochester. New York (19.20) 
4. Robert DeBusk: Stanford University. Palo Alto. California (21) 
C. Valvular disease 
I. Eugene Blackstone: University of Alabama. Birmingham. Alabama, (22) 
D. Arrhythmias and syncope 
I. Wishwa Kapoor: studies of syncope: University of Pittsburgh. Pittsburgh. Pennsylvania (23) 
III. Cost-benefit. decision analysis 
A. Milton Weinstein: studies of hypertension and coronary artery bypass surgery: Harvard School of Public Health. Boston. Massachusetts (24-27) 
B. Shan Cretin: University of California. Los Angeles. California (28) 
C. Lee Goldman: Harvard University (29) 
D. Stephen Pauker: studies of coronary surgery and pacemakers; Tufts New England Medical Center. Boston. Massachusetts (30-32) 
E. David Eddy: confidence profile method: Duke University. Durham. North Carolina (33) 
of multicenter trials (for example, the Coronary Artery 
Surgery Study and the Thrombolysis in Myocardial Infarc- 
tion Trials have been very useful in this regard). 
Improving Accessibility of Models 
Using standardized key words in publications. The com- 
mittee noted that a second important barrier to more wide- 
spread use of cardiovascular modeling was the difficulty that 
potential users have in learning about the existence of 
models and how to use them. One fairly simple method to 
assist potential users in locating cardiovascular models 
would be to have all model developers use a uniform set of 
key words in their published manuscripts. This set of key 
words would allow bibliographic searching using the Index 
Medicus or computerized Medline searches. 
Table 2. Barriers to Adoption of Cardiovascular Models 
Nonstandard terminology 
Difference in measurement standards 
Lack of awareness of models 
Lack of model validation 
Many models difficult to use 
Creating a centralized data base or clearinghouse for 
models. Another method of improving access to users of 
models would be to have a centralized data base or clear- 
inghouse for cardiovascular-oriented models. The clearing- 
house could contain as little as a brief description of the 
model and the name of its developer, or could contain as 
much as the complete specifications of the model and all 
necessary documentation. Such a clearinghouse could be 
maintained either by professional societies (such as the 
American College of Cardiology or the Society for Medical 
Decision-Making), by independent entities (such as the 
Regenstrief Institute for Health Care) or by the National 
Library of Medicine. 
The committee felt strongly that the establishment of 
such a central clearinghouse should be explored. It recom- 
mended that the clearinghouse include a basic description of 
each model and direct interested users to the developer of 
the model for a complete description of the model and 
instructions on its use. A clearinghouse that held complete 
specifications and documentation of models would have a 
potential advantage because the user would not have to 
contact the developer of the model. The committee felt, 
however, that this advantage was more than outweighed by 
several drawbacks, especially the possibility that the model 
54A HLATKY AND SELKER 
PROJECTS AND PRIORITIES IN CARDIOVASCULAR MODELING 
JACC Vol. 14, No. 3 
September 1989:52A4A 
could be used inappropriately or that some of the basic 
limitations of the model could be misunderstood without 
communications between the user and the developer. Fur- 
thermore, in the case of commercial products, complete 
divulgence of the contents of the model may be limited for 
proprietary reasons. Thus, the committee felt that any 
clearinghouse would be most useful by bringing interested 
users together with model developers. 
Validation and Dissemination of Models 
The committee identified several general reasons to rec- 
ommend that the initial use of a cardiovascular model should 
involve close communication between the user of the model 
and its developer or developers. First, any differences in the 
way the user of a model and its developer measure key 
variables should be identified and minimized. Second, vali- 
dation of how a model performs in other institutions is 
important evidence of its value and, therefore, validation 
studies should be carefully planned and truly collaborative. 
Because failure of a model to replicate results in another 
institution is a major shortcoming, validation studies must be 
fair and unbiased. Poor replication of a model because of 
differences in data specification or misunderstanding of how 
to use the model may halt acceptance of potentially useful 
clinical tools. 
On the other hand, overly hasty acceptance of models is 
also to be decried. Potential users of clinical prediction rules 
should understand model limitations and apply proper meth- 
odologic standards in evaluation. In particular, validation 
studies in an independent study population are essential to 
assess the performance of models. Such studies are partic- 
ularly useful when performed in other institutions. Addition- 
ally, models intended for clinical use should be tested to 
determine their value over and above clinical judgment and 
to demonstrate any impact on clinical care. In this way, 
models intended for clinical use should meet the same type 
of standards before being accepted as would any other new 
procedures. 
The committee was also concerned about uncritical ac- 
ceptance of the results of models. These models are meant to 
supplement and not replace clinical judgment. Marked dis- 
crepancies between a model and clinical judgment should be 
examined closely. In this regard, clinicians should treat 
models as they would any other consultant. This consider- 
ation has an important corollary. To the extent that decision 
models are used to dictate management of groups of pa- 
tients, as might be done in setting standards of care or 
reimbursement policy, model performance must be particu- 
larly well validated. This need arises from the lesser oppor- 
tunity for seasoned clinical judgment to override the model if 
errors are present. Thus, direct translation of models into 
policy or payment systems must be particularly cautious. 
Table 3. Priority Areas for Modeling 
1. Prevention strategies for coronary heart disease 
2. Cardiovascular therapies in the elderly 
3. Integrated treatment strategies for acute myocardial infarction 
Priorities and Recommendations 
Clinical questions in need of further modeling. Priorities 
for future work can be divided into two main areas, namely 
clinical questions in need of further modeling and method- 
ologic questions that will advance the state of the art. Most 
clinical modeling arises from clinical dilemmas encountered 
by physicians in their everyday practice. The committee 
recognized that most models will continue to be prompted by 
pressing clinical problems. Beyond the areas that are already 
topics of cardiovascular modeling (Table l), there are many 
additional clinical questions that might benefit from model- 
ing. Potential areas of work include the management of 
patients with ventricular ectopic rhythm, especially patients 
with evidence of left ventricular dysfunction; management of 
patients who have been “ruled out” for myocardial infarc- 
tion; evaluation of the ambulatory patient with chest pain; 
evaluation of patients with suspected pulmonary embolism; 
evaluation of patients with syncope and management of 
coronary artery disease in patients undergoing vascular 
surgery procedures. From a clinical perspective, many other 
areas of interest could clearly be identified to meet the needs 
of practicing physicians. 
In assigning priorities for cardiovascular modeling 
projects, the committee felt that major consideration should 
be given to problems that either present major public health 
hazards or involve allocation of considerable medical care 
resources, or both. It identified three areas in particular that 
merit further investigation (Table 3). 
The optimal approach to the prevention of coronary artery 
disease. Considerable uncertainty remains about the best 
method of prevention, and various strategies need to be 
evaluated in terms of cost-benefit and cost-effectiveness 
analyses. In particular, the relative merits of the strategy of 
population-wide interventions versus the strategy of screen- 
ing for high risk individuals and initiating individualized 
therapy need to be assessed. New models should take into 
account the availability of newer cholesterol-lowering drugs, 
as well as the new research findings about cholesterol- 
lowering and the value of aspirin in primary prevention. 
Management of cardiovascular disease in the elderly. This 
will be an increasing problem as the average lifespan length- 
ens and therapeutic interventions are more often considered 
in this segment of the population. A major question that 
could be addressed is the use of expensive technology such 
as coronary bypass surgery and coronary angioplasty in the 
elderly population. Clinical cardiovascular modeling could 
analyze possible age-related changes in the efficacy of such 
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therapies. In addition, quality of life is often more important 
than length of life to the elderly patient. Considerable 
methodologic work needs to be performed to take quality of 
life into account in the evaluation of clinical management 
strategies. 
The strategy for the treatment of patients with acute 
myocardial infarction. The advent of the thrombolytic ther- 
apy has markedly changed the approach to patients with 
acute myocardial infarction. Although thrombolytic agents 
clearly lower the mortality rate, the need for further therapy 
after thrombolysis (such as angioplasty, bypass surgery and 
secondary prevention) needs to be addressed. Cost-effective 
strategies for identifying the high risk patient also need to be 
evaluated. In view of the relative frequency of acute myo- 
cardial infarction and its role of a major cause of premature 
death, the critical evaluation of various strategies in the care 
of myocardial infarction should be a major priority. 
Other priorities in advancing the field of cardiovascular 
modeling. These include development of common nomen- 
clature for clinical variables and increased recognition of 
methodologic standards in performing cardiovascular mod- 
eling. Major effort needs to be expended to make models 
more helpful to the physicians. In particular, models should 
be made easier to use and easier to understand. The com- 
mittee felt that considerable work needs to be performed to 
understand the needs of physicians in decision making in 
daily practice and improve the interface between models and 
physicians. Finally, the possible role of regulation of models 
that provide therapeutic advice to physicians must be ad- 
dressed. 
Conclusions. The committee found that there is a wide 
variety of ongoing projects in clinical cardiovascular model- 
ing. These projects cover several clinical domains and use 
several methods. Despite the successes to date, the commit- 
tee found that models are not well disseminated or fre- 
quently used; standard nomenclature and improved commu- 
nications networks would ameliorate these shortcomings. 
The committee felt that cardiovascular models should be 
evaluated as done for other medical technologies, with an 
initial development phase where they are used in a few 
institutions, a critical evaluation phase in a wide number of 
institutions and a phase of widespread dissemination. Work 
in the future should focus on strengthening the value of 
models to clinical decision makers and developing models in 
priority areas such as prevention of coronary disease, car- 
diovascular care in the elderly and management of acute 
myocardial infarction. 
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